Sign In
Buy SI
Silvergate Capital Earnings Calls
| Release date | May 13, 2026 |
| EPS estimate | -$0.440 |
| EPS actual | -$0.410 |
| EPS Surprise | 6.82% |
| Revenue estimate | 14.536M |
| Revenue actual | 16.708M |
| Revenue Surprise | 14.94% |
| Release date | Mar 10, 2026 |
| EPS estimate | -$0.420 |
| EPS actual | -$0.380 |
| EPS Surprise | 9.52% |
| Revenue estimate | 12.793M |
| Revenue actual | 14.416M |
| Revenue Surprise | 12.69% |
| Release date | Nov 11, 2025 |
| EPS estimate | -$0.313 |
| EPS actual | -$0.480 |
| EPS Surprise | -53.15% |
| Revenue estimate | 12.787M |
| Revenue actual | 11.756M |
| Revenue Surprise | -8.06% |
| Release date | Sep 09, 2025 |
| EPS estimate | -$0.630 |
| EPS actual | -$64.47 |
| EPS Surprise | -10,131.71% |
| Revenue estimate | 9.87M |
| Revenue actual | 11.013M |
| Revenue Surprise | 11.58% |
Last 4 Quarters for Silvergate Capital
Below you can see how SI performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Sep 09, 2025 |
| Price on release | $14.98 |
| EPS estimate | -$0.630 |
| EPS actual | -$64.47 |
| EPS surprise | -10,131.71% |
| Date | Price |
|---|---|
| Sep 03, 2025 | $15.04 |
| Sep 04, 2025 | $15.26 |
| Sep 05, 2025 | $14.85 |
| Sep 08, 2025 | $15.90 |
| Sep 09, 2025 | $14.98 |
| Sep 10, 2025 | $12.74 |
| Sep 11, 2025 | $15.00 |
| Sep 12, 2025 | $15.71 |
| Sep 15, 2025 | $14.94 |
| 4 days before | -0.399% |
| 4 days after | -0.267% |
| On release day | -14.95% |
| Change in period | -0.665% |
| Release date | Nov 11, 2025 |
| Price on release | $11.36 |
| EPS estimate | -$0.313 |
| EPS actual | -$0.480 |
| EPS surprise | -53.15% |
| Date | Price |
|---|---|
| Nov 05, 2025 | $11.29 |
| Nov 06, 2025 | $11.22 |
| Nov 07, 2025 | $11.05 |
| Nov 10, 2025 | $11.00 |
| Nov 11, 2025 | $11.36 |
| Nov 12, 2025 | $15.00 |
| Nov 13, 2025 | $14.70 |
| Nov 14, 2025 | $14.70 |
| Nov 17, 2025 | $14.47 |
| 4 days before | 0.620% |
| 4 days after | 27.38% |
| On release day | 32.04% |
| Change in period | 28.17% |
| Release date | Mar 10, 2026 |
| Price on release | $13.05 |
| EPS estimate | -$0.420 |
| EPS actual | -$0.380 |
| EPS surprise | 9.52% |
| Date | Price |
|---|---|
| Mar 04, 2026 | $13.11 |
| Mar 05, 2026 | $13.03 |
| Mar 06, 2026 | $13.01 |
| Mar 09, 2026 | $13.39 |
| Mar 10, 2026 | $13.05 |
| Mar 11, 2026 | $14.01 |
| Mar 12, 2026 | $14.62 |
| Mar 13, 2026 | $14.82 |
| Mar 16, 2026 | $15.28 |
| 4 days before | -0.458% |
| 4 days after | 17.09% |
| On release day | 7.36% |
| Change in period | 16.55% |
| Release date | May 13, 2026 |
| Price on release | $13.53 |
| EPS estimate | -$0.440 |
| EPS actual | -$0.410 |
| EPS surprise | 6.82% |
| Date | Price |
|---|---|
| May 07, 2026 | $12.77 |
| May 08, 2026 | $13.20 |
| May 11, 2026 | $13.22 |
| May 12, 2026 | $13.37 |
| May 13, 2026 | $13.53 |
| May 14, 2026 | $15.59 |
| May 15, 2026 | $15.63 |
| May 18, 2026 | $14.78 |
| May 19, 2026 | $14.93 |
| 4 days before | 5.95% |
| 4 days after | 10.35% |
| On release day | 15.23% |
| Change in period | 16.91% |
Silvergate Capital Earnings Call Transcript Summary of Q1 2026
Shoulder Innovations reported a strong start to 2026 with Q1 net revenue of $16.7M, up 65% year-over-year and 16% sequentially, and a healthy gross margin of 77.7%. Management raised full-year 2026 revenue guidance to $65M–$68M (37%–44% growth vs. 2025), driven by rapid new surgeon adoption, higher utilization among existing surgeons (total implant volume up 51% YoY), improved ASPs, and product progress (expanded InSet I-135RFX commercial launch, N22 Glenosphere limited release, and >500 patients in the clinical registry). The company is investing in commercial expansion (adding W-2 commercial leaders and educational symposiums) and R&D, including a strategic partnership to develop a shoulder-specific micro-robotic system integrated with its ProVoyance planning platform (targeting a 510(k) submission in 2027). Q1 operating spend rose (SG&A and R&D), producing a larger net loss and adjusted EBITDA loss versus prior year, but the company has $108.5M in cash and expects lower cash burn from Q2 onward while pursuing cash-flow breakeven as scale and operating leverage improve. Management emphasizes a focused, surgeon-centric platform strategy and sees substantial underpenetrated market opportunity ahead.
